B. Riley Begins Coverage on AMAG Pharmaceuticals (AMAG)
Investment analysts at B. Riley started coverage on shares of AMAG Pharmaceuticals (NASDAQ:AMAG) in a research note issued on Thursday. The brokerage set a “neutral” rating and a $16.00 price target on the specialty pharmaceutical company’s stock. B. Riley’s price target would suggest a potential upside of 14.70% from the company’s current price.
Other equities analysts also recently issued research reports about the stock. Cantor Fitzgerald reaffirmed a “hold” rating and set a $21.00 price target on shares of AMAG Pharmaceuticals in a research note on Thursday, September 28th. Cowen reaffirmed a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Thursday, August 10th. Zacks Investment Research downgraded shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 17th. Janney Montgomery Scott reaffirmed a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Tuesday, October 17th. Finally, Morgan Stanley cut their target price on shares of AMAG Pharmaceuticals from $26.00 to $22.00 and set an “overweight” rating on the stock in a research note on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $23.38.
Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) opened at $13.95 on Thursday. AMAG Pharmaceuticals has a 1 year low of $11.93 and a 1 year high of $36.83. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.48 and a current ratio of 1.59.
TRADEMARK VIOLATION WARNING: “B. Riley Begins Coverage on AMAG Pharmaceuticals (AMAG)” was originally posted by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/12/07/b-riley-begins-coverage-on-amag-pharmaceuticals-amag.html.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.